A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants
An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Chiesi Clinical trial Info
- Telefonnummer: +390521279715
- E-Mail: clinicaltrials_info@chiesi.com
Studienorte
-
-
-
Leeds, Vereinigtes Königreich
- Fortrea Clinical Research Unit (CRU) Limited
-
Kontakt:
- Firas Almezedi
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Key Inclusion Criteria:
- BMI (body mass index) between 18.0 and 30.0 kg/m²
- Weight between 45 and 100 kg
- Non-smokers or ex-smokers (<5 pack-years)
- Clinically healthy based on medical history and examination
- Normal vital signs
- Normal ECG
- Willingness to comply with contraception requirements
Key Exclusion Criteria:
- Recent participation in another clinical study
- Significant medical conditions
- Abnormal laboratory values
- Positive HIV or hepatitis tests
- Recent infection or COVID-19
- Drug or alcohol abuse
- Use of prohibited medications
- Gastrointestinal surgery affecting absorption
- Hypersensitivity to study drugs
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Fixed Sequence Treatment
CHF10196 - Pantoprazole - Pantoprazole with CHF10196
|
Treatment Period 1: CHF10196 single dose administration on Day1; Treatment Period 2: CHF10196 single dose administration after pantoprazole single dose administration on Day13 Treatment Period 2: Pantoprazole single dose administration from Day8 to Day13 |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PK parameter: AUC0-∞
Zeitfenster: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: AUC0-t
Zeitfenster: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: Cmax
Zeitfenster: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety and tolerability: Incidence of adverse events (AE)
Zeitfenster: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs: PR
Zeitfenster: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - RR
Zeitfenster: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - blood pressure
Zeitfenster: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for ECG
Zeitfenster: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196 |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for ECG (HR)
Zeitfenster: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baseline for ECG recording of heart rate (HR) Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196). |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for laboratory abnormalities
Zeitfenster: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number of participants with abnormal blood laboratory test results.
Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: AUC0-24h
Zeitfenster: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)
|
From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
|
Additional pharmacokinetic parameters: CL/F
Zeitfenster: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the total body clearance (CL/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: t1/2
Zeitfenster: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the terminal half-life (t1/2) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: Vd/F
Zeitfenster: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: tmax
Zeitfenster: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Benjamen Monaghan, Fortrea Clinical Research Unit (CRU)
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CLI-10196AA1-05
- 1014440 (Andere Kennung: IRAS)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .